Show simple item record

FieldValueLanguage
dc.contributor.authorOehlers, Stefan
dc.date.accessioned2020-02-12
dc.date.available2020-02-12
dc.date.issued2019-06-17
dc.identifier.citationStefan H. Oehlers; Revisiting hypoxia therapies for tuberculosis. Clin Sci (Lond) 28 June 2019; 133 (12): 1271–1280. doi: https://doi.org/10.1042/CS20190415en_AU
dc.identifier.urihttps://hdl.handle.net/2123/21833
dc.description.abstractThe spectre of the coming post-antibiotic age demands novel therapies for infectious diseases. Tuberculosis, caused by Mycobacterium tuberculosis, is the single deadliest infection throughout human history. M. tuberculosis has acquired antibiotic resistance at an alarming rate with some strains reported as being totally drug resistant. Host-directed therapies attempt to overcome the evolution of antibiotic resistance by targeting relatively immutable host processes. Here I hypothesise the induction of hypoxia via anti-angiogenic therapy will be an efficacious host-directed therapy against tuberculosis. I argue that anti-angiogenic therapy is a modernisation of industrial revolution era sanatoria treatment for tuberculosis, and present a view of the tuberculosis granuloma as a “bacterial tumour” that can be treated with anti-angiogenic therapies to reduce bacterial burden and spare host immunopathology. I suggest two complementary modes of action, induction of bacterial dormancy and activation of host Hypoxia Induced Factor-mediated immunity, and define the experimental tools necessary to test this hypothesis.en_AU
dc.description.sponsorshipThis work was supported by an Australian National Health and Medical Research Council CJ Martin Early Career Fellowship APP1053407 and Project Grant APP1099912; The University of Sydney Fellowship G197581; NSW Ministry of Health under the NSW Health Early-Mid Career Fellowships Scheme H18/31086; and the Kenyon Family Foundation Inflammation Award (S.H.O.).en_AU
dc.language.isoenen_AU
dc.publisherPortland Pressen_AU
dc.relationNHMRC APP1053407 and APP1099912en_AU
dc.subjectmycobacterial infectionen_AU
dc.subjecthypoxiaen_AU
dc.titleRevisiting hypoxia therapies for tuberculosisen_AU
dc.typeArticleen_AU
dc.subject.asrcFoR::110801 - Medical Bacteriologyen_AU
dc.subject.asrcFoR::110707 - Innate Immunityen_AU
dc.identifier.doi10.1042/CS20190415
dc.type.pubtypePost-printen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.